Precision biosciences stock.
DTIL Stock Analysis: Potential +608.72% Increase According to Analysts Forecasts. DTIL stock, the ticker symbol for Precision BioSciences Inc, closed at a price of 0.42 on September 19, 2023. The 5 analysts offering 12-month price forecasts for DTIL have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 1.40.
The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Shares of Precision BioSciences (DTIL 2.79%) fell as much as 51.4% today after the company announced updated data from its lead drug candidate at the annual meeting of the American Society of ...Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing …Nov 28, 2023 · The inducement, part of their Inducement Award Plan, allows the employee to purchase 160,000 shares of Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting ... Jun 21, 2022 · Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ...
Dec 1, 2023 · Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More.
DTIL stock, representing Precision BioSciences Inc, had an interesting performance on September 19, 2023. According to data from CNN Money, the 5 analysts offering 12-month price forecasts for DTIL have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of …
Precision Biosciences Stock Earnings. The value each DTIL share was expected to gain vs. the value that each DTIL share actually gained. Precision Biosciences ( DTIL) reported Q3 2023 earnings per share (EPS) of -$0.14, beating estimates of -$0.18 by 21.37%. In the same quarter last year, Precision Biosciences 's earnings per share (EPS) was ...Nov 28, 2023 · The inducement, part of their Inducement Award Plan, allows the employee to purchase 160,000 shares of Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting ... DURHAM, N.C.--(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel …Precision BioSciences, Inc. Stock price BOERSE MUENCHEN Equities PBS US74019P1084 Biotechnology & Medical Research Real-time BOERSE MUENCHEN. Other stock markets. 09:13:47 2023-11-21 am EST 5-day change 1st Jan Change ...
Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...
Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is ...
Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.60June 23, 2022 at 12:08 PM · 3 min read. Shares of Precision BioSciences, Inc. DTIL have remained up so far this week as the company has entered into an exclusive worldwide in vivo gene-editing ...Earnings Summary. For their last quarter, Precision BioSciences (DTIL) reported earnings of -$0.10 per share, beating the Zacks Consensus Estimate of $-0.19 per share. This reflects a positive ...DURHAM, N.C.--(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the …Tuesday, April 18, 2023. Precision Biosciences Expects Approximately $158M In Cash And Cash Equivalents As Of March 31, 2023. The Company's Management Also Believes That The Existing Cash And Cash ...
Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis.Precision BioSciences is slated to present a poster at the 64th ASH Annual Meeting between December 10th and 13th. See why DTIL stock is a Buy.DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and... | March 29, 2023Sep 19, 2023 · In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00. Precision BioSciences (NASDAQ:DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a ...Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update. March 15, 2022 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding - basic and diluted 58,688,102 52,031,740 Precision Biosciences, Inc. Consolidated Balance Sheets Data ...
Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of …Mullen Automotive, Inc. Common Stock. $0.2205 +0.0496 29.02%. Precision BioSciences, Inc. Common Stock (DTIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ... Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $4.00.The company’s shares opened today at $0.57. Roy ...Apple Inc. Common Stock. $191.45 +1.76 +0.93%. Precision BioSciences, Inc. Common Stock (DTIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Alberta Precision Labs (APL) is a medical laboratory that offers a wide range of diagnostic tests and services. If you need to book an appointment with APL, there are a few things you should know before you go.According to the issued ratings of 3 analysts in the last year, the consensus rating for Precision BioSciences stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for DTIL. The average twelve-month price prediction for Precision BioSciences is $3.00 with a high price target of $4.00 and a low price target of $2.00.
3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.
Why Is Precision BioSciences Stock Soaring Today? msn.com - August 16 at 3:33 PM: Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) finance.yahoo.com - August 6 at 8:38 AM: Precision BioSciences Inc Q2 Loss decreases, beats estimates markets.businessinsider.com - August 4 at 11:50 PM
Nov 6, 2023 · As of November 3, 2023, shares of Precision BioSciences were trading at $0.4256. Over the last 52-week period, the stock has experienced a decline of 68.38%. According to TipRanks, the average price target for DTIL is $2.58, with a high forecast of $4.00 and a low forecast of $1.00. In conclusion, investors will be closely monitoring Precision ... Additionally, Precision announced a common stock offering yesterday. The company will “sell 35,971,224 shares of its common stock at a price of $1.39 per share.”Specific Internship opportunities for Summer 2024 will be posted in January 2024. Please check back to our careers site for more specific opportunities then. Our …Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ... Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting... If you are looking for stocks with good return, Precision Biosciences Inc stock can be a bad, high-risk 1-year investment option. Precision Biosciences Inc real time quote is equal to 0.363 USD at 2023-12-03, but your current investment may be devalued in the future.Dec 1, 2023 · Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ... Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.
4 ngày trước ... Precision BioSciences Inc (DTIL:NASDAQ CM) の株価、株式情報、チャート、関連ニュースなど、企業概要や株価の分析をご覧いただけます。Precision BioScience (NASDAQ: DTIL) stock is rallying for a second straight day after the company announced a new partnership with Novartis (NYSE: NVS) after market close yesterday. Novartis is a ...Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See today’s best-performing stocks on TipRanks >> The company has a one-year ...Instagram:https://instagram. future fintechbest crypto for day tradingbest small cap companiespro.benzinga Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update. November 7, 2023 at 7:00 AM EST. PDF Version ... Weighted average shares of common stock outstanding-basic and diluted 115,174,752 110,849,196 Precision Biosciences, Inc. Condensed Balance Sheets Data ... govt tickerggb stocks Nov 28, 2023 · The inducement, part of their Inducement Award Plan, allows the employee to purchase 160,000 shares of Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting ... We can see from the most recent balance sheet that Precision BioSciences had liabilities of US$59.7m falling due within a year, and liabilities of US$118.1m due beyond that. Offsetting this, it had US$189.6m in cash and US$720.0k in receivables that were due within 12 months. So it can boast US$12.6m more liquid assets than total liabilities. 1943 steel lincoln penny value Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy.Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is ... Justin Zelin’s Buy rating for the Precision BioSciences stock is based on several factors. The company, which primarily focuses on in-vivo gene editing, is heading towards advancing its ARCUS ...